



SUVEN Life Sciences Ltd

Communication to investors December 2015

12-Feb-16

2015-16 Q3 results



Risk statement

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.



FINANCIAL QUICK VIEW

	FY 2015-16 Q3 to Q2	FY 2015-16 PE Sep 15
Growth in revenue	-4.96%	-16.84%
Growth in PAT	-28.34%	-31.72%
Growth in EBIDTA	-21.67%	-32.70%
Growth in Pre-R&D EBIDTA	-15.14%	-22.35%
Increase in R&D Costs	0.71%	13.75%
R&D to sales	13.02%	13.38%

12-Feb-16

2015-16 Q3 results



MAJOR PROFITABILITY RATIOS

	Q3 Dec 15	PE Dec 15
PAT to Income	15.21%	18.16%
EBIDTA to Income	24.56%	27.60%
Cash Flow to Income	19.09%	21.62%
Pre-R&D EBITDA to Income	37.58%	40.98%





12-Feb-16

2015-16 Q3 results




Q3 to Q2 COMPARISON

Current quarter to previous quarter





REVENUE COMPARISON




12-Feb-16

2015-16 Q3 results



PAT COMPARISON




12-Feb-16

2015-16 Q3 results



EBIDTA COMPARISON

Year on year




12-Feb-16

2015-16 Q3 results



R & D – EXPENDITURE

Year on year




12-Feb-16

2015-16 Q3 results



PRE-R&D EBIDTA




12-Feb-16

2015-16 Q3 results



PRE-R&D CASHFLOW

Year on year



12-Feb-16

2015-16 Q3 results



FINANCIAL SNAPSHOT

All figures are in INR Million, other than ratios and EPS

	2015-16 Q3	2015-16 Q2	Growth %	2014-15 Q3	Growth %	2015-16 PEdec15	2014-15 PEdec14	Growth %
Income	1,164.74	1,225.49	-4.96%	1,311.01	-11.16%	3,450.80	4,149.60	-16.84%
Pre-R&D EBITDA	437.75	515.83	-15.14%	633.93	-30.95%	1,414.09	1,821.00	-22.35%
Pre-R&D EBITDA Margin	37.58%	42.09%		48.35%		40.98%	43.88%	
EBITDA	286.06	365.20	-21.67%	486.93	-41.25%	952.40	1,415.12	-32.70%
EBITDA Margin	24.56%	29.80%		37.14%		27.60%	34.10%	
EBIT	240.86	320.22	-24.78%	457.85	-47.39%	833.18	1,324.06	-37.07%
EBIT Margin	20.68%	26.13%		34.92%		24.14%	31.91%	
Financing costs	15.39	13.95		10.06		38.56	35.00	
Taxes	48.28	58.98		125.53		167.83	371.05	
Net Profit after tax	177.19	247.29	-28.34%	322.27	-45.02%	626.79	918.01	-31.72%
NP Margin	15.21%	20.18%		24.58%		18.16%	22.12%	
EPS (basic & diluted not annualised)	1.39	1.94		2.73		4.92	7.78	
Paid up share capital (One Rupee Share)	127.28	127.28		127.28		127.28	127.28	
Depreciation	45.20	44.98		29.08		119.22	91.06	
R&D expenses	151.70	150.63	0.71%	147.00	3.20%	461.69	405.88	13.75%

12-Feb-16

2015-16 Q3 results

News Release



- Suven initiates Phase 2A trial of SUVN-502 in USA indicated for Alzheimer's disease
- During the period Suven secures 11 product patents covering Europe, Macau, Hong Kong, Japan, South Africa and ARIPO region.

12-Feb-16

2015-16 Q3 results